Phase Ib/IIa Study of SHR-1210 Combined With AIN457 for Patients With Late Stage MSS CRC Who Failed Second-line and Above Treatment
Latest Information Update: 03 Mar 2023
At a glance
- Drugs Camrelizumab (Primary) ; Secukinumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms SHR-1210-AIN457
Most Recent Events
- 12 Mar 2020 Planned initiation date changed from 1 Mar 2020 to 15 Mar 2020.
- 09 Mar 2020 New trial record